Immunome (IMNM) Change in Accured Expenses (2019 - 2026)

Immunome's Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$9.7 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 14.38% year-over-year to -$9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 24.13% YoY) and the FY2025 annual result came in at $4.5 million, down 66.55% from the prior year.
• Change in Accured Expenses was -$9.7 million for Q1 2026 at Immunome, down from $5.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.9 million in Q2 2024 and bottomed at -$9.7 million in Q1 2026.
• A 5-year average of $413470.6 and a median of $619000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 13155.81% in 2025, while the deepest fall reached 1373.69% in 2025.
• Immunome's Change in Accured Expenses stood at $549000.0 in 2022, then soared by 276.32% to $2.1 million in 2023, then tumbled by 97.92% to $43000.0 in 2024, then jumped by 13155.81% to $5.7 million in 2025, then tumbled by 270.98% to -$9.7 million in 2026.
• Business Quant data shows IMNM's Change in Accured Expenses at -$9.7 million in Q1 2026, $5.7 million in Q4 2025, and $6.7 million in Q3 2025.